RESUMO
An acute hepatitis C infection was diagnosed in three HIV-positive gay men, aged 43, 48 and 30 years, respectively. In all three, unprotected sexual intercourse and fisting was a universal risk factor for the infection. They all denied having used drugs intravenously, which is the most common risk factor. The third man had a documented proctitis (lymphogranuloma venereum) at the time when the HCV transmission must have taken place. No serious complications occurred during the acute HCV infection. Because the infection did not resolve spontaneously after a few months, all three men were treated with pegylated interferon and ribavirin. Recently, the number of cases of acute HCV infection has been seen to increase in The Netherlands. This may be due primarily to an increase in unprotected sexual intercourse and fisting. This hypothesis is supported by a documented increased prevalence of sexually transmissible diseases among gay men in The Netherlands. As acute infections may turn into chronic infections, treatment of an acute infection should be considered in order to prevent the chronic disease.
Assuntos
Infecções por HIV/complicações , Hepatite C/transmissão , Homossexualidade Masculina , Doenças Virais Sexualmente Transmissíveis/transmissão , Doença Aguda , Adulto , Antivirais/uso terapêutico , Hepatite C/tratamento farmacológico , Hepatite C/epidemiologia , Humanos , Linfogranuloma Venéreo/complicações , Masculino , Pessoa de Meia-Idade , Países Baixos/epidemiologia , Prevalência , Proctite/complicações , Ribavirina/uso terapêutico , Fatores de Risco , Comportamento Sexual , Doenças Virais Sexualmente Transmissíveis/tratamento farmacológico , Doenças Virais Sexualmente Transmissíveis/epidemiologiaRESUMO
The life expectancy of patients with an HIV infection has improved dramatically since the introduction of highly active anti-retroviral therapy (HAART). Retrospective studies have shown that since then, hospital admissions and mortality caused by a co-infection with hepatitis C virus (HCV) have increased. Patients with an HIV-HCV co-infection exhibit on average a more rapid progression to liver cirrhosis and liver failure than patients with an HCV monoinfection. It is expected that a co-infection with HCV will lead to serious complications among some of the HIV-infected population. It is therefore recommended that all HIV-infected patients be screened for a co-infection with HCV. The treatment of an HCV co-infection needs to be considered. The first choice therapy will probably be a combination of peginterferon and ribavirin, although final conclusions about the safety and efficacy are still awaited. A combination of ribavirin with zidovudine or didanosine is best avoided. Developments being made with new classes of drugs, such as HCV-specific protease inhibitors and polymerase inhibitors, seem promising.